一、审议通过了《关于调整 2023 年限制性股票激励计划相关事项的议案》 证券代码：688076 证券简称：诺泰生物 公告编号：2025-050 江苏诺泰澳赛诺生物制药股份有限公司 第四届董事会第二次会议决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏诺泰澳赛诺生物制药股份有限公司（以下简称"公司"）第四届董事会 第二次会议于2025 年 6月 26 日下午15:30 在公司会议室以现场与通讯方式召开， 会议通知于 2025 年 6 月 20 日以电子邮件方式送达全体董事。本次会议应出席董 事 9 人，实际出席董事 9 人，会议由董事长童梓权先生主持。会议的召开程序符 合有关法律法规、规范性文件和《公司章程》的规定，会议合法、有效。 经全体与会董事审议，本次会议以投票表决方式审议通过了以下议案： 议案内容：详见《江苏诺泰澳赛诺生物制药股份有限公司关于调整 2023 年 限制性股票激励计划相关事项的公告》（公告编号：2025-052）。本议案已经薪酬 与考核委员会审议通过。 表决结果：同意 7 票，反对 0 票， ...

Group 1 - The financing balance of the Sci-Tech Innovation Board increased by 1.234 billion yuan compared to the previous day, with 55 stocks seeing an increase of over 10 million yuan in financing balance [1] - As of June 10, the total margin balance of the Sci-Tech Innovation Board reached 154.686 billion yuan, an increase of 1.235 billion yuan from the previous trading day [1] - Among the stocks on the Sci-Tech Innovation Board, 399 had a financing balance exceeding 100 million yuan, with 18 stocks having a balance over 1 billion yuan [1] Group 2 - The stock with the highest net financing purchase was Haiguang Information, with a latest financing balance of 3.763 billion yuan, increasing by 628.779 million yuan, and the stock rose by 4.30% on that day [2] - Other notable stocks with significant net purchases included Zhongwei Company and Nuotai Biological, with net purchases of 64.465 million yuan and 55.095 million yuan respectively [2] - The average decline for stocks with net purchases exceeding 10 million yuan was 1.29%, while stocks with the highest gains included Huicheng Co., Junshi Biological, and Xinyu Ren, with increases of 12.53%, 9.24%, and 5.18% respectively [2] Group 3 - The average financing balance as a percentage of market capitalization for stocks with significant net purchases was 3.61%, with the highest ratio being 8.00% for Maixinlin [2] - Other stocks with high financing balance ratios included Zhongke Lanyun at 7.76%, Yuntian Lifi at 6.98%, and Maiwei Biological at 6.59% [2] - The sectors attracting financing interest included electronics, pharmaceuticals, and computers, with 20, 12, and 8 stocks respectively [2]

Group 1: Market Performance - The weight loss drug concept index rose by 1.46%, ranking 7th among concept sectors, with 27 stocks increasing in value [1] - Notable gainers included Zhongsheng Pharmaceutical, which hit the daily limit, and Hanyu Pharmaceutical, Yipinhong, and Tianenkang, with increases of 13.58%, 9.40%, and 9.35% respectively [1] - The sector experienced a net outflow of 600 million yuan in capital, with 23 stocks seeing net inflows, and 6 stocks receiving over 30 million yuan in net inflows [2] Group 2: Capital Flow - Leading the net inflow of capital was Lepu Medical, with a net inflow of 176 million yuan, followed by Hengrui Medicine and Ganli Pharmaceutical with net inflows of 164 million yuan and 117 million yuan respectively [2] - The top three stocks by net inflow ratio were Kexing Pharmaceutical, Lepu Medical, and Ganli Pharmaceutical, with net inflow ratios of 9.86%, 9.24%, and 8.74% respectively [3] Group 3: Stock Performance - The stock performance table indicated that Lepu Medical had a daily increase of 4.10% with a turnover rate of 8.77%, while Hengrui Medicine rose by 1.42% with a turnover rate of 0.75% [3] - Other notable performers included Tianenkang with a 9.35% increase and a turnover rate of 10.42%, and Kexing Pharmaceutical with a 6.40% increase and a turnover rate of 3.35% [4]

Market Overview - The Shanghai Composite Index closed at 3399.77 points, above the six-month moving average, with a gain of 0.43% [1] - The total trading volume of A-shares reached 13126.55 billion yuan [1] Stocks Breaking the Six-Month Moving Average - A total of 220 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Qitian Technology: 8.76% deviation, closing price at 14.00 yuan, with a daily gain of 16.86% and turnover rate of 21.88% [1] - Haochen Medical: 8.62% deviation, closing price at 3.12 yuan, with a daily gain of 9.86% and turnover rate of 7.25% [1] - Guangyun Technology: 8.13% deviation, closing price at 14.22 yuan, with a daily gain of 9.89% and turnover rate of 6.59% [1] Additional Stocks with Minor Deviations - Stocks with smaller deviation rates that have just crossed the six-month moving average include: - CITIC Special Steel: minor deviation, closing price at 20.30 yuan, with a daily gain of 10.69% [1] - Nanda Optoelectronics: minor deviation, closing price at 36.44 yuan, with a daily gain of 9.99% [1] -沃尔核材: minor deviation, closing price at 25.41 yuan, with a daily gain of 11.75% [1]

Market Overview - The Shanghai Composite Index closed at 3393.26 points, above the six-month moving average, with a change of 0.23% [1] - The total trading volume of A-shares reached 838.618 billion yuan [1] Stocks Breaking Six-Month Moving Average - A total of 184 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Qitian Technology: 11.69% deviation, closing price 14.38 yuan, with a daily increase of 20.03% and turnover rate of 15.50% [1] - Haochen Medical: 8.62% deviation, closing price 3.12 yuan, with a daily increase of 9.86% and turnover rate of 6.44% [1] - Jinyinhai: 7.58% deviation, closing price 21.00 yuan, with a daily increase of 9.66% and turnover rate of 6.43% [1] Additional Stocks with Deviation Rates - Other stocks with notable performance include: - Guangyun Technology: 7.45% deviation, closing price 14.13 yuan, with a daily increase of 9.20% and turnover rate of 4.78% [1] - Yaowang Technology: 5.93% deviation, closing price 7.12 yuan, with a daily increase of 7.88% and turnover rate of 13.64% [1] - Nuotai Biotech: 5.91% deviation, closing price 55.37 yuan, with a daily increase of 10.36% and turnover rate of 5.58% [1] Summary of Other Stocks - Additional stocks with lower deviation rates that have just crossed the six-month moving average include: - Guangdong Hongtu: just above the six-month line [1] - Xinhe Shares: just above the six-month line [1] - Songjing Shares: just above the six-month line [1]

Group 1 - The A-share market indices experienced a collective upward trend, with the STAR Market Biopharmaceutical Index showing significant strength [1] - The STAR Market Biopharmaceutical Index ETF (588700) rose by 2.25%, with a trading volume exceeding 18 million yuan and a turnover rate of 7.97%, indicating active trading [1] - Key constituent stocks such as Yuyuan Pharmaceutical, Shouyao Holdings-U, and Nuotai Bio saw increases of over 7% [1] Group 2 - Harvard University's Belfer Center report indicates that China has a strong opportunity to surpass the U.S. in biotechnology, particularly in drug development [2] - The report highlights that while the U.S. leads in five key technology areas, the gap in biotechnology is narrowing, with China emerging as a source of original innovation [2] - CITIC Securities notes that the American Society of Clinical Oncology (ASCO) annual meeting is the largest and most authoritative clinical oncology conference, with increasing representation of domestic innovative drug data [2] Group 3 - Century Securities reports that there are ongoing developments in the innovative drug sector, particularly with the collaboration between Bristol-Myers Squibb and BioNTech for a $9 billion joint development of a PD-L1/VEGF dual antibody [3] - The ASCO meeting showcased significant progress in dual antibodies and ADC fields, with new mechanisms and targets emerging, indicating a differentiated layout in early clinical stages [3] - The competitiveness of domestic innovative drug pipelines on a global scale is expected to continue to rise, with a long-term positive outlook on the international expansion of innovative drugs [3]

Policy Developments - The National Health Commission is promoting the implementation of the "Blood Fee Waiver, No Need to Run Once" policy, aiming for full compliance by the end of 2025 across all blood stations and medical institutions in the country [1] Drug and Device Approvals - LuKang Pharmaceutical announced that its subsidiary has received approval for the consistency evaluation of Cimetidine Injection, which is used to treat symptoms caused by excessive stomach acid [2] - Baiyunshan reported that its subsidiary has received a drug registration certificate for Tadalafil Tablets, which are primarily used to treat erectile dysfunction [3] - Fuyuan Pharmaceutical announced that its subsidiary has received a drug registration certificate for Bromhexine Hydrochloride Oral Solution, suitable for treating respiratory diseases related to mucus secretion or clearance [4] Capital Market Activities - Tianxing Medical's IPO on the Sci-Tech Innovation Board has been terminated due to the withdrawal of its sponsor [5] - NuoTai Bio and NuoWeiZan signed a strategic cooperation agreement for a synthetic biology project, planning to establish a joint biopharmaceutical company [6] Industry Events - A medical team in the UK is experimenting with processing healthy human feces into freeze-dried powder to help patients infected with superbugs, showing promising results [8] - Huazhong University of Science and Technology has opened the first brain-computer interface outpatient clinic in Central China, aiming to provide assessments and consultations for patients [9] - Kelong Pharmaceutical responded to accusations regarding its Ergotamine Capsules, clarifying that the product is classified as a dietary supplement rather than a drug [10] - Green Valley Pharmaceutical has halted production of the controversial drug Mannitol Sodium Capsules due to expired registration and ongoing scrutiny of its clinical trials [11] - Weili Zhibo Biotechnology has received approval from the China Securities Regulatory Commission for its IPO and the full circulation of its unlisted shares [12][14]

Core Viewpoint - The strategic cooperation between Nuotai Bio and Nuowei Zhan aims to establish a joint biopharmaceutical company focused on synthetic biology technology, enhancing both companies' capabilities in the field [1][2][3] Group 1: Partnership Details - Nuotai Bio will hold a 51% stake in the joint venture, while Nuowei Zhan will hold 49%, with respective contributions of 45.90% and 44.10% [1] - The partnership will be implemented in two phases, with the first phase focusing on the renovation of existing capacities and the application for DMF of raw materials [1] - The ultimate goal is to establish an annual production capacity of approximately 10 tons of raw materials and corresponding formulations [1] Group 2: Company Strengths - Nuotai Bio is a leading company in the peptide drug sector, having overcome production bottlenecks and achieved industry-leading production levels of over 10 kilograms per batch for drugs like Semaglutide and Aibowei [2] - Nuowei Zhan specializes in the development of functional proteins and high molecular organic materials, holding a leading position in the field of in vitro diagnostic reagents [2] Group 3: Strategic Implications - The collaboration is expected to leverage the strengths of both companies in synthetic biology and peptide drugs, driving product and technology upgrades [3] - The strategic partnership aims to establish an advanced synthetic biology technology platform, promoting interdisciplinary collaboration and industry upgrades [3]

Core Points - Notai Bio (688076) closed at 50.17 yuan on June 6, 2025, up 4.39% from last week's 48.06 yuan [1] - The company's market capitalization is currently 11.282 billion yuan, ranking 41st out of 150 in the chemical pharmaceutical sector and 1402nd out of 5148 in the A-share market [1] Company Announcements - Notai Bio announced a cash dividend of 0.80 yuan per share and a stock bonus of 0.40 shares per share, with the record date set for June 11, 2025 [2] - The total cash dividend distribution amounts to 179.896 million yuan based on the pre-distribution total share capital of 224,870,915 shares, resulting in a new total share capital of 314,819,281 shares after the distribution [2] - The profit distribution and stock bonus plan was approved at the annual shareholders' meeting on May 23, 2025 [2] Tax Implications - Different tax policies apply to various types of shareholders regarding cash dividends, with natural person shareholders holding unrestricted shares for over one year exempt from personal income tax on dividend income [2] - For qualified foreign institutional investors (QFII) and Hong Kong market investors, a 10% withholding tax applies, resulting in a net cash dividend of 0.72 yuan per share [2] - Other institutional investors and corporate shareholders will receive a pre-tax cash dividend of 0.80 yuan per share [2] Earnings Impact - After the implementation of the stock bonus plan, the diluted earnings per share for the fiscal year 2024 is projected to be 1.34 yuan based on the new total share capital [2]

Core Viewpoint - Nanjing Novogene Bioinformatics Technology Co., Ltd. has signed a strategic cooperation agreement with Jiangsu Nuotai Aosaino Biopharmaceutical Co., Ltd. to establish a joint venture focused on synthetic biology, aiming to enhance technological advancements and project collaboration in the field [1][2]. Agreement Signing Overview - The strategic cooperation agreement does not require approval from the company's board of directors or shareholders [2]. - The agreement does not constitute a related party transaction or a major asset restructuring [2]. - The specific investment scale and construction plan for the joint venture will be determined later, indicating uncertainty [1][2]. Parties Involved - Jiangsu Nuotai Aosaino Biopharmaceutical Co., Ltd. is a publicly listed company with a registered capital of 224.87 million yuan and was established in March 2009 [2][3]. - The company has total assets of approximately 507.80 million yuan and a net profit attributable to shareholders of 40.44 million yuan [3]. Joint Venture Details - The joint venture will be co-owned, with Nanjing Novogene holding 49% and Jiangsu Nuotai holding 51% [1][4]. - The project will be implemented in two phases, with the first phase focusing on the renovation and expansion of existing production capacities [4]. - The ultimate goal is to establish an annual production capacity of approximately 10 tons of raw materials and corresponding formulations [4]. Investment and Funding - The specific investment amount will be confirmed by both parties [4]. - Initial funding will come from self-owned funds, with potential project financing for the second phase [4]. Governance Structure - The joint venture will have a board of directors composed of three directors from Jiangsu Nuotai and two from Nanjing Novogene [5]. - The management team will include a general manager nominated by Jiangsu Nuotai and other key positions filled through mutual agreement [5][6]. Operational Management - The joint venture will operate independently, with both parties sharing operational risks and responsibilities [6]. - The agreement includes non-competition clauses and stipulates that both parties will support each other in their respective areas of expertise [6][7]. Impact on Company - This strategic cooperation is expected to enhance the company's core competitiveness in the synthetic biology sector and extend its industrial value chain [7]. - The establishment of the joint venture is subject to regulatory approval and is not expected to significantly impact the company's 2025 performance [7][8].